Optomed Oyj

Major Shareholding Notification • Jun 5, 2023

Disclosure 433974

Optomed Oyj - Major shareholder announcements

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed PlcStock Exchange Release5 June 2023 at 13.30, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Cenova Capital (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held by Notifier through its funds (Shanghai Cenova Innovation Venture Fund (Limited Partnership), Alnair Investment and Cenova China Healthcare Fund IV, L.P.) has decreased to 9.96 per cent of all of the registered shares in Optomed on 2 June 2023. The total number of the Company's registered shares amounts to 16,541,355 shares. Each share entitles to one vote. The total position of Notifier subject to the notification: +----------------+----------+------------------------------------+---------+ | |% of |% of shares and voting rights |Total of | | |shares and|through financial instruments (total|both in %| | |voting |of B) |(A+B) | | |rights | | | | |(total | | | | |of A) | | | +----------------+----------+------------------------------------+---------+ |Resulting |9.96 % |- |9.96 % | |situation on the| | | | |date on | | | | |which threshold | | | | |was crossed or | | | | |reached | | | | +----------------+----------+------------------------------------+---------+ |Position of |14.36 % |- |14.36 % | |previous | | | | |notification | | | | |(if applicable) | | | | +----------------+----------+------------------------------------+---------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights +------------+-----------------+----------------+-----------------+-----------+ |Class/type |Number of shares and voting rights|% of shares and voting rights| |of shares | | | | | | | |ISIN code | | | +------------+-----------------+----------------+-----------------+-----------+ |Direct |Indirect |Direct |Indirect | |(SMA 9:5) |(SMA 9:6 and 9:7)|(SMA 9:5) |(SMA 9:6 and 9:7)| +------------+-----------------+----------------+-----------------+-----------+ |FI4000410881|1,647,771 |- |9.96 % |- | +------------+-----------------+----------------+-----------------+-----------+ |SUBTOTAL A |2,211,664 |9.96 % | +------------+-----------------+----------------+-----------------+-----------+ Information in relation to the person subject to the notification obligation as contained in the notification The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: +-----------------+----------------+-----------------------------+------------+ |Name |% of shares and |% of shares and voting rights|Total of | | |voting rights |through financial instruments|both | +-----------------+----------------+-----------------------------+------------+ |Cenova China |0% of shares and|- |0% of shares| |Healthcare GP IV |100% voting | |and 100% | |Limited |rights | |voting | | | | |rights of | | | | |Cenova China| | | | |Healthcare | | | | |Fund IV, L.P| +-----------------+----------------+-----------------------------+------------+ |Shanghai Cenova |1% of shares and|- |1% of shares| |Bioventure Equity|100% voting | |and 100% | |Investment Fund |rights | |voting | |Management | | |rights of | |Enterprise | | |Shanghai | | | | |Cenova | | | | |Innovation | | | | |Venture Fund| | | | |(Limited | | | | |Partnership)| +-----------------+----------------+-----------------------------+------------+ |Shanghai Cenova |100% |- |100% of | |Innovation | | |Alnair | |Venture | | |Investment | |Fund (Limited | | | | |Partnership) | | | | +-----------------+----------------+-----------------------------+------------+ Further enquiries Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com www.optomed.com Optomed in Brief Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.